These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 27769352)
41. Cell-based protein stabilization assays for the detection of interactions between small-molecule inhibitors and BRD4. Schulze J; Moosmayer D; Weiske J; Fernández-Montalván A; Herbst C; Jung M; Haendler B; Bader B J Biomol Screen; 2015 Feb; 20(2):180-9. PubMed ID: 25266565 [TBL] [Abstract][Full Text] [Related]
42. 4-Acyl Pyrrole Derivatives Yield Novel Vectors for Designing Inhibitors of the Acetyl-Lysine Recognition Site of BRD4(1). Hügle M; Lucas X; Weitzel G; Ostrovskyi D; Breit B; Gerhardt S; Einsle O; Günther S; Wohlwend D J Med Chem; 2016 Feb; 59(4):1518-30. PubMed ID: 26731611 [TBL] [Abstract][Full Text] [Related]
43. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma. Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994 [TBL] [Abstract][Full Text] [Related]
44. Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design. Duffy BC; Liu S; Martin GS; Wang R; Hsia MM; Zhao H; Guo C; Ellis M; Quinn JF; Kharenko OA; Norek K; Gesner EM; Young PR; McLure KG; Wagner GS; Lakshminarasimhan D; White A; Suto RK; Hansen HC; Kitchen DB Bioorg Med Chem Lett; 2015 Jul; 25(14):2818-23. PubMed ID: 26022843 [TBL] [Abstract][Full Text] [Related]
45. Structural Mechanism of Transcriptional Regulator NSD3 Recognition by the ET Domain of BRD4. Zhang Q; Zeng L; Shen C; Ju Y; Konuma T; Zhao C; Vakoc CR; Zhou MM Structure; 2016 Jul; 24(7):1201-8. PubMed ID: 27291650 [TBL] [Abstract][Full Text] [Related]
46. Nonequivalent response to bromodomain-targeting BET inhibitors in oligodendrocyte cell fate decision. Chiang CM Chem Biol; 2014 Jul; 21(7):804-6. PubMed ID: 25036774 [TBL] [Abstract][Full Text] [Related]
47. BET proteins: Biological functions and therapeutic interventions. Guo J; Zheng Q; Peng Y Pharmacol Ther; 2023 Mar; 243():108354. PubMed ID: 36739915 [TBL] [Abstract][Full Text] [Related]
48. Molecular design of Stat3-derived peptide selectivity between BET proteins Brd2 and Brd4 in ovarian cancer. Zhu L; Ding X J Mol Recognit; 2018 Feb; 31(2):. PubMed ID: 28983974 [TBL] [Abstract][Full Text] [Related]
49. Establishment of environment-sensitive probes targeting BRD3/BRD4 for imaging and therapy of tumor. Gao Y; Zhang J; Li J; Song S; Zhang S; Liu Q; Wang X; Zhao J; Xia C; Xiao Y; Liu T Eur J Med Chem; 2023 Sep; 257():115478. PubMed ID: 37269669 [TBL] [Abstract][Full Text] [Related]
50. The BET family in immunity and disease. Wang N; Wu R; Tang D; Kang R Signal Transduct Target Ther; 2021 Jan; 6(1):23. PubMed ID: 33462181 [TBL] [Abstract][Full Text] [Related]
51. Insights into the Mechanism of Curaxin CBL0137 Epigenetic Activity: The Induction of DNA Demethylation and the Suppression of BET Family Proteins. Maksimova V; Popova V; Prus A; Lylova E; Usalka O; Sagitova G; Zhidkova E; Makus J; Trapeznikova E; Belitsky G; Yakubovskaya M; Kirsanov K Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629054 [TBL] [Abstract][Full Text] [Related]
52. Targeting the Bromome: are we there yet? Müller S Future Med Chem; 2016 Sep; 8(13):1529-32. PubMed ID: 27578167 [No Abstract] [Full Text] [Related]
53. BET Proteins: An Approach to Future Therapies in Transplantation. Suarez-Alvarez B; Rodriguez RM; Ruiz-Ortega M; Lopez-Larrea C Am J Transplant; 2017 Sep; 17(9):2254-2262. PubMed ID: 28173625 [TBL] [Abstract][Full Text] [Related]
54. Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia. Picaud S; Leonards K; Lambert JP; Dovey O; Wells C; Fedorov O; Monteiro O; Fujisawa T; Wang CY; Lingard H; Tallant C; Nikbin N; Guetzoyan L; Ingham R; Ley SV; Brennan P; Muller S; Samsonova A; Gingras AC; Schwaller J; Vassiliou G; Knapp S; Filippakopoulos P Sci Adv; 2016 Oct; 2(10):e1600760. PubMed ID: 27757418 [TBL] [Abstract][Full Text] [Related]
55. Targeting Transcription Factors for Cancer Treatment. Lambert M; Jambon S; Depauw S; David-Cordonnier MH Molecules; 2018 Jun; 23(6):. PubMed ID: 29921764 [TBL] [Abstract][Full Text] [Related]
56. The Role of Bromodomain Testis-Specific Factor, BRDT, in Cancer: A Biomarker and A Possible Therapeutic Target. Bourova-Flin E; Chuffart F; Rousseaux S; Khochbin S Cell J; 2017; 19(Suppl 1):1-8. PubMed ID: 28580303 [TBL] [Abstract][Full Text] [Related]
57. Highly Parallel Quantification and Compartment Localization of Transcription Factors and Nuclear Proteins. Federation AJ; Nandakumar V; Searle BC; Stergachis A; Wang H; Pino LK; Merrihew G; Ting YS; Howard N; Kutyavin T; MacCoss MJ; Stamatoyannopoulos JA Cell Rep; 2020 Feb; 30(8):2463-2471.e5. PubMed ID: 32101728 [TBL] [Abstract][Full Text] [Related]
58. Preparation data of the bromodomains BRD3(1), BRD3(2), BRD4(1), and BRPF1B and crystallization of BRD4(1)-inhibitor complexes. Hügle M; Lucas X; Weitzel G; Ostrovskyi D; Breit B; Gerhardt S; Schmidtkunz K; Jung M; Schüle R; Einsle O; Günther S; Wohlwend D Data Brief; 2016 Jun; 7():1370-4. PubMed ID: 27158652 [TBL] [Abstract][Full Text] [Related]
59. Targeting TOR dependence in cancer. Janes MR; Fruman DA Oncotarget; 2010 May; 1(1):69-76. PubMed ID: 20657741 [TBL] [Abstract][Full Text] [Related]